Do analysts prefer AVCT or SCLP?

Avacta Group presently has a consensus target price of GBX 99, suggesting a potential upside of 35.62%. Given Avacta Group's stronger consensus rating and higher possible upside, research analysts plainly believe Avacta Group is more favorable than Scancell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avacta Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Scancell 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, AVCT or SCLP?

Scancell has higher revenue and earnings than Avacta Group. Scancell is trading at a lower price-to-earnings ratio than Avacta Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avacta Group £113K 3,026.90 -£30.08M -£9.66 N/A Scancell £4.71M 23.04 -£6.75M -£0.55 N/A

Is AVCT or SCLP more profitable?

Scancell has a net margin of -116.98% compared to Avacta Group's net margin of -33,961.06%. Scancell's return on equity of 90.29% beat Avacta Group's return on equity. Company Net Margins Return on Equity Return on Assets Avacta Group -33,961.06% -2,929.47% -21.80% Scancell -116.98% 90.29% -45.28%

Does the media prefer AVCT or SCLP?

In the previous week, Avacta Group had 1 more articles in the media than Scancell. MarketBeat recorded 2 mentions for Avacta Group and 1 mentions for Scancell. Scancell's average media sentiment score of 0.67 beat Avacta Group's score of 0.00 indicating that Scancell is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avacta Group 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Scancell 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate SCLP or PRTC?

PureTech Health has a consensus price target of GBX 508, suggesting a potential upside of 325.46%. Given PureTech Health's stronger consensus rating and higher probable upside, analysts clearly believe PureTech Health is more favorable than Scancell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scancell 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Is SCLP or PRTC more profitable?

Scancell has a net margin of -116.98% compared to PureTech Health's net margin of -2,355.32%. Scancell's return on equity of 90.29% beat PureTech Health's return on equity. Company Net Margins Return on Equity Return on Assets Scancell -116.98% 90.29% -45.28% PureTech Health -2,355.32% -31.98% -13.39%

Does the media prefer SCLP or PRTC?

In the previous week, Scancell and Scancell both had 1 articles in the media. PureTech Health's average media sentiment score of 0.75 beat Scancell's score of 0.67 indicating that PureTech Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scancell 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PureTech Health 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Scancell (SCLP) Competitors

GBX 10.16 +0.07 (+0.64%)

As of 09/11/2026 12:38 PM Eastern

Compare

SCLP vs. AVCT, HZD, PRTC, ARIX, and CIR

Should you buy Scancell stock or one of its competitors? Scancell's main competitors and comparable companies include Avacta Group (AVCT), Horizon Discovery Group plc (HZD.L) (HZD), PureTech Health (PRTC), Arix Bioscience (ARIX), and Circassia Group (CIR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Scancell compare to Avacta Group?

Avacta Group (LON:AVCT) and Scancell (LON:SCLP) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

Avacta Group has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, Scancell has a beta of 0.687, suggesting that its stock price is 31% less volatile than the broader market.

3.1% of Avacta Group shares are held by institutional investors. Comparatively, 1.5% of Scancell shares are held by institutional investors. 47.7% of Avacta Group shares are held by insiders. Comparatively, 13.2% of Scancell shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Avacta Group presently has a consensus target price of GBX 99, suggesting a potential upside of 35.62%. Given Avacta Group's stronger consensus rating and higher possible upside, research analysts plainly believe Avacta Group is more favorable than Scancell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Scancell	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Scancell has a net margin of -116.98% compared to Avacta Group's net margin of -33,961.06%. Scancell's return on equity of 90.29% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avacta Group	-33,961.06%	-2,929.47%	-21.80%
Scancell	-116.98%	90.29%	-45.28%

In the previous week, Avacta Group had 1 more articles in the media than Scancell. MarketBeat recorded 2 mentions for Avacta Group and 1 mentions for Scancell. Scancell's average media sentiment score of 0.67 beat Avacta Group's score of 0.00 indicating that Scancell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avacta Group	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Scancell	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Scancell has higher revenue and earnings than Avacta Group. Scancell is trading at a lower price-to-earnings ratio than Avacta Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avacta Group	£113K	3,026.90	-£30.08M	-£9.66	N/A
Scancell	£4.71M	23.04	-£6.75M	-£0.55	N/A

Summary

Avacta Group beats Scancell on 10 of the 16 factors compared between the two stocks.

How does Scancell compare to Horizon Discovery Group plc (HZD.L)?

Horizon Discovery Group plc (HZD.L) (LON:HZD) and Scancell (LON:SCLP) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Horizon Discovery Group plc (HZD.L) has higher revenue and earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than Horizon Discovery Group plc (HZD.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Horizon Discovery Group plc (HZD.L)	£54.63M	0.00	N/A	-£5.50	N/A
Scancell	£4.71M	23.04	-£6.75M	-£0.55	N/A

In the previous week, Scancell had 1 more articles in the media than Horizon Discovery Group plc (HZD.L). MarketBeat recorded 1 mentions for Scancell and 0 mentions for Horizon Discovery Group plc (HZD.L). Scancell's average media sentiment score of 0.67 beat Horizon Discovery Group plc (HZD.L)'s score of 0.00 indicating that Scancell is being referred to more favorably in the news media.

Company	Overall Sentiment
Horizon Discovery Group plc (HZD.L)	Neutral
Scancell	Positive

Horizon Discovery Group plc (HZD.L) has a net margin of 0.00% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Horizon Discovery Group plc (HZD.L)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A
Scancell	-116.98%	90.29%	-45.28%

1.5% of Scancell shares are held by institutional investors. 13.2% of Scancell shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Scancell beats Horizon Discovery Group plc (HZD.L) on 7 of the 10 factors compared between the two stocks.

How does Scancell compare to PureTech Health?

Scancell (LON:SCLP) and PureTech Health (LON:PRTC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

In the previous week, Scancell and Scancell both had 1 articles in the media. PureTech Health's average media sentiment score of 0.75 beat Scancell's score of 0.67 indicating that PureTech Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scancell	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PureTech Health	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Scancell has a net margin of -116.98% compared to PureTech Health's net margin of -2,355.32%. Scancell's return on equity of 90.29% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scancell	-116.98%	90.29%	-45.28%
PureTech Health	-2,355.32%	-31.98%	-13.39%

Scancell has higher revenue and earnings than PureTech Health. Scancell is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scancell	£4.71M	23.04	-£6.75M	-£0.55	N/A
PureTech Health	£4.66M	62.83	-£91.86M	-£46.00	N/A

PureTech Health has a consensus price target of GBX 508, suggesting a potential upside of 325.46%. Given PureTech Health's stronger consensus rating and higher probable upside, analysts clearly believe PureTech Health is more favorable than Scancell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scancell	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

1.5% of Scancell shares are held by institutional investors. Comparatively, 30.7% of PureTech Health shares are held by institutional investors. 13.2% of Scancell shares are held by company insiders. Comparatively, 13.4% of PureTech Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Scancell has a beta of 0.687, suggesting that its share price is 31% less volatile than the broader market. Comparatively, PureTech Health has a beta of 0.771, suggesting that its share price is 23% less volatile than the broader market.

Summary

PureTech Health beats Scancell on 10 of the 15 factors compared between the two stocks.

How does Scancell compare to Arix Bioscience?

Scancell (LON:SCLP) and Arix Bioscience (LON:ARIX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Arix Bioscience has higher revenue and earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scancell	£4.71M	23.04	-£6.75M	-£0.55	N/A
Arix Bioscience	£14.16M	0.00	£14.96M	£0.11	N/A

In the previous week, Scancell had 1 more articles in the media than Arix Bioscience. MarketBeat recorded 1 mentions for Scancell and 0 mentions for Arix Bioscience. Scancell's average media sentiment score of 0.67 beat Arix Bioscience's score of 0.00 indicating that Scancell is being referred to more favorably in the media.

Company	Overall Sentiment
Scancell	Positive
Arix Bioscience	Neutral

1.5% of Scancell shares are owned by institutional investors. Comparatively, 41.3% of Arix Bioscience shares are owned by institutional investors. 13.2% of Scancell shares are owned by company insiders. Comparatively, 20.7% of Arix Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Arix Bioscience has a net margin of 105.64% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Arix Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scancell	-116.98%	90.29%	-45.28%
Arix Bioscience	105.64%	6.41%	2.18%

Scancell has a beta of 0.687, suggesting that its share price is 31% less volatile than the broader market. Comparatively, Arix Bioscience has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

Summary

Arix Bioscience beats Scancell on 9 of the 12 factors compared between the two stocks.

How does Scancell compare to Circassia Group?

Scancell (LON:SCLP) and Circassia Group (LON:CIR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

Circassia Group has a net margin of 0.00% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Circassia Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scancell	-116.98%	90.29%	-45.28%
Circassia Group	N/A	N/A	N/A

Circassia Group has higher revenue and earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scancell	£4.71M	23.04	-£6.75M	-£0.55	N/A
Circassia Group	£27.90M	0.00	N/A	£0.01	N/A

1.5% of Scancell shares are held by institutional investors. 13.2% of Scancell shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Scancell had 1 more articles in the media than Circassia Group. MarketBeat recorded 1 mentions for Scancell and 0 mentions for Circassia Group. Scancell's average media sentiment score of 0.67 beat Circassia Group's score of 0.00 indicating that Scancell is being referred to more favorably in the media.

Company	Overall Sentiment
Scancell	Positive
Circassia Group	Neutral

Summary

Scancell and Circassia Group tied by winning 5 of the 10 factors compared between the two stocks.

Get Scancell News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCLP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SCLP vs. The Competition

Export

Metric	Scancell	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£137.70M	£3.85B	£7.16B	£2.51B
Dividend Yield	N/A	3.65%	2.57%	6.25%
P/E Ratio	-18.48	14.18	274.94	366.83
Price / Sales	23.04	1,374.96	685.44	89,753.13
Price / Cash	7.86	106.50	76.65	27.89
Price / Book	-26.08	15.12	10.33	6.33
Net Income	-£6.75M	-£22.86M	£3.50B	£5.89B
7 Day Performance	6.33%	-4.34%	-3.32%	-0.69%
1 Month Performance	5.67%	0.54%	-0.53%	0.00%
1 Year Performance	11.09%	40.74%	23.51%	19.96%

Scancell Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SCLP Scancell	N/A	GBX 10.17 +0.6%	N/A	+11.1%	£137.70M	£4.71M	N/A	51	News Coverage Gap Up High Trading Volume
AVCT Avacta Group	1.7272 of 5 stars	GBX 70.55 +2.4%	GBX 99 +40.3%	+32.7%	£330.56M	£113K	N/A	120
HZD Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A	N/A	£302.98M	£54.63M	N/A	416
PRTC PureTech Health	3.0815 of 5 stars	GBX 120.60 flat	GBX 508 +321.2%	+4.9%	£295.69M	£4.66M	N/A	300	News Coverage
ARIX Arix Bioscience	N/A	N/A	N/A	N/A	£183.73M	£14.16M	1,290.91	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:SCLP) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Scancell (SCLP) Competitors

SCLP vs. AVCT, HZD, PRTC, ARIX, and CIR

How does Scancell compare to Avacta Group?

Summary

How does Scancell compare to Horizon Discovery Group plc (HZD.L)?

Summary

How does Scancell compare to PureTech Health?

Summary

How does Scancell compare to Arix Bioscience?

Summary

How does Scancell compare to Circassia Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCLP vs. The Competition

Scancell Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Scancell (SCLP) Competitors

SCLP vs. AVCT, HZD, PRTC, ARIX, and CIR

How does Scancell compare to Avacta Group?

Which has more risk and volatility, AVCT or SCLP?

Do insiders & institutionals have more ownership in AVCT or SCLP?

Do analysts prefer AVCT or SCLP?

Is AVCT or SCLP more profitable?

Does the media prefer AVCT or SCLP?

Which has preferable earnings & valuation, AVCT or SCLP?

Summary

How does Scancell compare to Horizon Discovery Group plc (HZD.L)?

Which has preferable earnings & valuation, HZD or SCLP?

Does the media refer more to HZD or SCLP?

Is HZD or SCLP more profitable?

Do institutionals and insiders believe in HZD or SCLP?

Summary

How does Scancell compare to PureTech Health?

Does the media prefer SCLP or PRTC?

Is SCLP or PRTC more profitable?

Which has better valuation & earnings, SCLP or PRTC?

Do analysts rate SCLP or PRTC?

Do institutionals & insiders hold more shares of SCLP or PRTC?

Which has more volatility and risk, SCLP or PRTC?

Summary

How does Scancell compare to Arix Bioscience?

Which has stronger earnings & valuation, SCLP or ARIX?

Does the media favor SCLP or ARIX?

Do institutionals & insiders believe in SCLP or ARIX?

Is SCLP or ARIX more profitable?

Which has more risk and volatility, SCLP or ARIX?

Summary

How does Scancell compare to Circassia Group?

Is SCLP or CIR more profitable?

Which has preferable valuation and earnings, SCLP or CIR?

Do insiders & institutionals believe in SCLP or CIR?

Does the media favor SCLP or CIR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCLP vs. The Competition

Scancell Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools